Loading...
XKRX
005690
Market cap528mUSD
Jul 11, Last price  
12,140.00KRW
1D
-6.04%
1Q
29.01%
Jan 2017
133.91%
Name

Pharmicell Co Ltd

Chart & Performance

D1W1MN
P/E
115.06
P/S
11.23
EPS
105.51
Div Yield, %
—
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
14.83%
Revenues
64.85b
+15.34%
12,262,427,0008,327,605,0007,188,425,0006,368,840,00010,282,423,52011,111,800,24033,405,394,27020,155,408,36025,176,279,99027,839,155,88025,197,458,94028,351,801,13032,481,967,12037,752,047,60050,893,545,76060,181,806,97056,227,378,92564,851,303,830
Net income
6.33b
+76.95%
-907,860,000-4,432,368,000-3,953,213,000-13,832,579,000-18,172,653,000-17,642,754,530-25,700,634,600-28,768,437,020-6,390,211,570-676,712,100-39,196,611,390-12,680,884,1704,347,128,2805,241,801,2509,450,907,1608,261,768,8203,577,983,6306,331,277,000
CFO
3.50b
-70.39%
-745,665,0002,383,405,000-5,141,365,000-5,550,394,000-16,166,405,990-11,868,349,760-2,687,726,820-8,772,026,860-2,411,175,620988,968,270-2,007,324,1003,404,989,340-75,498,8808,978,054,530-5,222,199,6407,914,448,21011,814,411,6903,498,232,890
Earnings
Aug 11, 2025

Profile

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
URL
http://www.pharmicell.com/
IPO date
May 20, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
64,851,304
15.34%
56,227,379
-6.57%
60,181,807
18.25%
Cost of revenue
54,608,794
51,099,670
45,659,952
Unusual Expense (Income)
NOPBT
10,242,510
5,127,709
14,521,855
NOPBT Margin
15.79%
9.12%
24.13%
Operating Taxes
(67,302)
1,154,074
(4,915,804)
Tax Rate
22.51%
NOPAT
10,309,812
3,973,635
19,437,659
Net income
6,331,277
76.95%
3,577,984
-56.69%
8,261,769
-12.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
258,699
2,637,517
16,794,663
Long-term debt
1,113,306
975,980
213,135
Deferred revenue
214,015
279,224
371,929
Other long-term liabilities
4,537,845
3,689,206
(5,960,997)
Net debt
(8,108,389)
(10,457,531)
2,647,018
Cash flow
Cash from operating activities
3,498,233
11,814,412
7,914,448
CAPEX
(4,278,211)
(6,021,517)
(18,957,716)
Cash from investing activities
(6,799,986)
5,915,783
(20,532,117)
Cash from financing activities
(3,215,164)
(18,713,126)
(269,807)
FCF
3,031,544
726,208
(75,491)
Balance
Cash
11,200,837
14,025,369
25,959,881
Long term investments
(1,720,442)
45,659
(11,599,101)
Excess cash
6,237,829
11,259,659
11,351,690
Stockholders' equity
37,141,762
31,099,539
(108,006,164)
Invested Capital
85,639,204
69,460,921
198,973,152
ROIC
13.29%
2.96%
9.63%
ROCE
11.15%
5.87%
14.39%
EV
Common stock shares outstanding
59,502
60,004
59,958
Price
8,280.00
36.41%
6,070.00
-46.28%
11,300.00
-13.41%
Market cap
492,679,789
35.27%
364,224,365
-46.24%
677,526,304
-13.39%
EV
484,571,400
353,766,834
680,173,322
EBITDA
13,305,412
7,969,117
16,707,116
EV/EBITDA
36.42
44.39
40.71
Interest
101,368
866,883
746,199
Interest/NOPBT
0.99%
16.91%
5.14%